Impact Factor
3.47
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
2.06
2,415 total citations
h5-index
35
h5 depth signal
Cited share
70.7%
877 of 1,240
Total citations
2,415
Citation footprint
Metric signal
1.95
External metric anchor
Self-citation
10.4%
252 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
Japan
3,073
United States
1,083
Germany
646
China
607
South Korea
575
Citing Fields of Research
Oncology
2,510
Cancer & Development
1,120
Liver & Colon Cancer
1,114
Immunology
813
Breast Cancer
775
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
7,457
Articles tracked across the journal lifetime
Indexed publication set
1,240
877 cited publications
Last 12 months
566
47.2 publications/month
Open access share
10.8%
61 OA publications in the last year
Leading citing country
Japan
3,073 citing publications
Leading citing field
Oncology
2,510 citing publications
Latest tracked publication
1 October 2026
10 recent records available
Coverage & Indexing History
v1n2, 1981-
v1n2, 1981-
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Liver & Colon Cancer
Immunology
Lung Cancer
Digestive Disorders
Cancer & Development
Breast Cancer
Issuing & Sponsoring Bodies
Contributor
International Institute of Anticancer Research
Broad Categories
Neoplasms
Digestive Disorders
Liver & Colon Cancer
Immunology
Prostate Cancer
Urology
Lung Cancer
Cancer, Autophagy & Apoptosis
MeSH Descriptors
Medical Oncology
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.21873/anticanres.18425
Open DOI
Retraction
02
DOI 10.21873/anticanres.18424
Open DOI
Corrigenda
03
DOI 10.21873/anticanres.18423
Open DOI
ABSTRACTS OF THE 36th ANNUAL MEETING OF THE ITALIAN SOCIETY OF URO-ONCOLOGY (SIUrO): 1-3 October 2026, Turin, Italy
04
05
DOI 10.21873/anticanres.18421
Open DOI
Well-differentiated SMARCB1-deficient Pancreatic Malignancy With Indolent Liver Metastases
06
07
08
DOI 10.21873/anticanres.18418
Open DOI
Pembrolizumab plus Chemotherapy for Synchronous Multiple Primary Esophageal and Gingival Squamous Cell Carcinomas
09
DOI 10.21873/anticanres.18417
Open DOI
From Genomic Insight to Clinical Impact: Dramatic Response in RET Fusion–positive Pancreatic Cancer
10
Bibliographical & Catalog Notes
Title from cover.
Also issued online.
Vol. 1, no. 1 (JAN 1981)19911216 Notice not published Printed on acid-free paper